Support PBS listing for pembrolizumab
6 May 2019
Following the November 2018 PBAC meeting, pembrolizumab has been resubmitted to the Pharmaceutical Benefits Advisory Committee (PBAC) meeting in July 2019 to seek reimbursement on the PBS for the adjuvant treatment of patients with resected stage III melanoma.
Listing on the Australian Pharmaceutical benefits scheme would provide subsidised access to this treatment for resected stage III melanoma.
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
Submissions will be accepted until Wed 12 June 2019, and they can be made as follows:
- Email your input directly to the PBAC at CommentsPBAC@health.gov.au
- Mail your submission to the PBAC Secretariat: MDP 952, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601
- There is also an online portal for submission
Please note that if you are submitting via the online portal, there are two submissions for pembrolizumab. Please select the option that states Indication: Melanoma – the first pembrolizumab option.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Prestigious award in pathology for Professor Scolyer
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay inspires others to help end melanoma and so can you
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
A dilemma no mother-to-be should face
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Join little Madi and Bettina in the fight against melanoma
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!
Sun Protection: Facts and Controversies
MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.
Shannan Ponton joins our March for a cure
Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life.
Surprising finding in rare form of melanoma get patients closer to personalised medicine
Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.
Using new technology to prevent melanoma
Innovation is helping to prevent melanoma developing in the first place.
Research review of 2017
Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.
Translational research funding boost
A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.
New research to guide clinicians to more accurately stage and manage melanoma patients
New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.
Founding father recognised for outstanding cancer care
Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.
Melanoma researchers shine at the State's premier cancer awards ceremony
Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.
Enhancing melanoma treatment response through gut bacteria
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
Melanoma March is just around the corner!
2018 will be bigger than ever, and a little bit different.
Comparing melanoma risk in similar populations across different latitudes
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.